MedTrace Logo

To Evaluate Clinical Efficacy and Safety of Diabetes-Specific Formula (Nutren Diabetes)

NCT05859165 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 233

Last updated 2025-11-24

No results posted yet for this study

Summary

This study has a parallel, non-inferiority design, comparing the 24h AUC of Nutren Diabetes group with Fresubin Diabetes group at 2-4 days since the start of formal intervention.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nutren Diabetes

Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day

DIETARY_SUPPLEMENT

Fresubin Diabetes

Product replace phase: 1-5 days, tube feeding, 25kcal/kg/day Formal intervention phase:7 days, tube feeding, 25kcal/kg/day

Sponsors & Collaborators

  • Nestle Health Science

    collaborator INDUSTRY

  • Société des Produits Nestlé (SPN)

    lead INDUSTRY

Principal Investigators

  • Wei Chen · Peking Union Medical College Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-01
Primary Completion
2025-03-18
Completion
2025-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859165 on ClinicalTrials.gov